Latest News Feed
Thirty-three Navy SEAL veterans were treated with a bone marrow mesenchymal stem cell (MSC) derived extracellular vesicle isolate product (EVIP) for Osteoarthritis (OA) of the knee, shoulder, elbow, hip, ankle, or wrist.
Extracellular Vesicle Isolate Product ExoFlo Shows Strong Potential to Treat COVID-19, Post-Acute COVID-19 Syndrome, and Chronic Post-COVID-19 Syndrome; 60-patient trial to be conducted nationally at ambulatory infusion sites
Medical professionals report dramatic and consistent success in treating patients gravely ill with COVID-19-associated Acute Respiratory Distress Syndrome (ARDS)
Fourth IND Application approval for investigational extracellular vesicle (EV) product ExoFlo
Extracellular vesicle product ExoFlo clinical trials to address early-stage COVID-19.
Extracellular Vesicle Isolate Product ExoFlo Shows Strong Potential to Treat COVID-19, Post-Acute COVID-19 Syndrome, and Chronic Post-COVID-19 Syndrome; 60-patient trial to be conducted nationally at ambulatory infusion sites
Medical professionals report dramatic and consistent success in treating patients gravely ill with COVID-19-associated Acute Respiratory Distress Syndrome (ARDS)
New Allograft Joins Market Leading ExoFlo™ Extracellular Vesicles in Direct Biologics Product Line
The expanded Access Program provides a pathway for patients to gain access to treatment with ExoFlo outside of the active Phase II research clinical trial.
